---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-395031"
form_type: "8-K"
ticker: "BLSM"
cik: "0001839970"
company_name: "BlossomHill Therapeutics, Inc."
filed_at: "2026-09-18T11:15:07+00:00"
generated_at: "2026-09-18T11:20:15.822391+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BlossomHill Q2 net loss $23.8M; IPO raises $168.3M; FDA Fast Track for lung cancer drug

## Summary
- Q2 2026 net loss $23.8M ($8.75/share) vs $13.2M ($5.51/share) in Q2 2025.
- R&D expenses $21.4M (up from $12.5M); G&A $3.3M (up from $1.6M).
- Cash $95.4M at June 30; August IPO gross proceeds $168.3M fund ops into Q2 2028.
- FDA Fast Track granted for BH-30643 in EGFR C797S-positive NSCLC after 3rd-gen TKI.
- Phase 1 SOLARA data: 45% ORR, 88% DCR in C797S-resistant patients; more milestones ahead.

## SEC filing metadata
- accession: 0001193125-26-395031
- form_type: 8-K
- ticker: BLSM
- cik: 0001839970
- company_name: BlossomHill Therapeutics, Inc.
- filed_at: 2026-09-18T11:15:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1839970/000119312526395031/0001193125-26-395031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1839970/000119312526395031/d266261d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-395031
- JSON: https://secwatch.observer/filing/0001193125-26-395031.json
- Plain text: https://secwatch.observer/filing/0001193125-26-395031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.